Novo nordisk achieves primary objectives of onwards 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in hba1c vs insulin glargine u100 in onwards 1

BagsvÆrd , denmark , 3 june 2022 – novo nordisk today announced headline results from the main phases of onwards 1 (52 weeks) and onwards 6 (26 weeks) phase 3a trials with once-weekly insulin icodec.

NVO Ratings Summary

NVO Quant Ranking